Fentanyl buccal - BioDelivery Sciences

Drug Profile

Fentanyl buccal - BioDelivery Sciences

Alternative Names: BEMA-Fentanyl; Breakyl; Fentanyl buccal soluble film; Fentanyl transmucosal - BioDelivery Sciences; Onsolis; Painkyl

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT USA
  • Developer BioDelivery Sciences International; Meda; TTY Biopharm
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 09 Aug 2017 BioDelivery Sciences plans to launch fentanyl buccal in USA in the first half of 2018
  • 15 May 2017 BioDelivery Science International intends to submit a regulatory application with US FDA to qualify new manufacturer Collegium Pharmaceutical in 2018
  • 09 Mar 2017 USPTO issues patent for fentanyl buccal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top